Accessibility Menu
CytoMed Therapeutics logo

CytoMed Therapeutics(NASDAQ) GDTC

Market Cap$9.97MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2023)-79%
5 YearN/A
1 Year-54%
1 Month-16%
$0.83
-1.52%
-0.01Today
After hours$0.78-$0.05 (-6.35%)
CytoMed Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 0.812026-08-12
CytoMed Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-3.75%USD 0.842026-08-05
1 month-15.82%USD 0.962026-07-13
3 month-8.15%USD 0.882026-05-14
Year to date-39.44%USD 1.342025-12-31
1 year-54.32%USD 1.772025-08-12
3 year-79.53%USD 3.952023-08-11
Since inception-78.93%USD 4.002023-04-14

CytoMed Therapeutics Financials at a Glance

Market Cap

$9.97MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

SGD 642.64K

Net Income (TTM)

-SGD 4.85M

EPS (TTM)

-$0.26

P/E Ratio

-3.23

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$0.83

Volume

14,666

Open

$0.84

Previous Close

$0.81

Daily Range

$0.78 - $0.86

52-Week Range

$0.68 - $3.68

Estimated Earnings Date

Jun 30, 2026

GDTC News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About CytoMed Therapeutics

CytoMed Therapeutics Limited is a biopharmaceutical company focused on developing advanced cellular immunotherapies to combat various human malignancies. Founded in 2018 and based in Singapore, the company is currently in the pre-clinical development phase, with innovative products aimed at enhancing cancer treatment.

Products and Services
  • CTM-N2D: Engineered gamma delta T cells targeting cancer cells
  • iPSC-gdNKT: Hybrid cells combining gamma delta T cells and natural killer cells
  • CTM-GDT: Expanded gamma delta T cells for broad-spectrum cancer recognition
Growth Outlook
  • Strong pipeline with multiple investigational products in development
  • Potential market expansion as immunotherapy gains traction in oncology
  • Strategic partnerships may enhance research capabilities and funding
Financial Highlights
  • Recent quarterly revenue of 167,945 SGD, showing growth potential
  • Cash and cash equivalents of 2,095,489 SGD, providing operational runway
  • Current ratio of 5.17 indicates strong liquidity position
CytoMed Therapeutics Limited is positioned in the biotechnology sector, focusing on innovative therapies that leverage the body's immune system to fight cancer. The company's lead product, CTM-N2D, utilizes engineered gamma delta T cells, which are designed to enhance the immune response against tumors. Additionally, the development of iPSC-gdNKT and CTM-GDT reflects a commitment to advancing cellular immunotherapy. The growth outlook for CytoMed is promising, with a robust pipeline of investigational products that could address significant unmet needs in cancer treatment. As the field of immunotherapy continues to evolve, CytoMed's innovative approaches may capture market interest and drive future revenue growth. The company’s strategic partnerships and collaborations could further bolster its research capabilities and financial resources. Financially, CytoMed has demonstrated a solid liquidity position, with a current ratio of 5.17, indicating that it can cover its short-term liabilities comfortably. The recent quarterly revenue of 167,945 SGD suggests a positive trajectory, while the cash reserves provide a buffer for ongoing research and development activities. Overall, CytoMed Therapeutics Limited presents an intriguing opportunity for investors interested in the biotechnology sector, particularly in the area of cancer immunotherapy.
AI Generated • Jul 28, 2026

Industry

Biotechnology

Sector

Health Care

Employees

42

CEO

Wee Kiat Tan, PhD

Website

www.cytomed.sg

Headquarters

Singapore, CE 149544, SG

GDTC Financials

Key Financial Metrics (TTM)

Gross Margin

-20.48%

Operating Margin

-672.18%

Net Income Margin

-754.66%

Return on Equity

-70.74%

Return on Capital

-64.32%

Return on Assets

-60.74%

Earnings Yield

-30.96%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$9.97MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

11.83M

Volume

14.67K

Avg. Volume

80.95K

Financials (TTM)

Gross Profit

-SGD 131.63K

Operating Income

-SGD 4.32M

EBITDA

-SGD 5.27M

Operating Cash Flow

-SGD 5.38M

Capital Expenditure

-SGD 952.57K

Free Cash Flow

-SGD 6.34M

Cash & ST Invst.

SGD 2.10M

Total Debt

SGD 482.56K

CytoMed Therapeutics Performance Analysis

CytoMed Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31SGD 0N/A
20232023-12-31SGD 0N/A
20242024-12-31SGD 52,006N/A
20252025-12-31SGD 248,269377.4%
CytoMed Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-03-3188.2%
Q22025-06-300.1%
Q32025-09-3052.0%
Q42025-12-31-18.1%
CytoMed Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31SGD -0.2141420.0%
20232023-12-31SGD -0.2939.5%
20242024-12-31SGD -0.16-43.6%
20252025-12-31SGD -0.2660.3%
CytoMed Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-03-3126.8%
Q22025-06-30-0.1%
Q32025-09-3022.5%
Q42025-12-31-89.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

SGD 167.95K

+134.7%

Gross Profit

-SGD 555.65K

-544.0%

Gross Margin

-3.31%

N/A

Market Cap

$9.97MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$237.45K

N/A

Employees

42

N/A

Net Income

-SGD 1.73M

-17.7%

EBITDA

-SGD 2.22M

-237.7%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

SGD 2.10M

-57.8%

Total Debt

SGD 482.56K

+4.2%

Accounts Receivable

SGD 103.86K

+453.1%

Inventory

SGD 1.07M

+27.3%

Long Term Debt

SGD 422.12K

+1.2%

Short Term Debt

SGD 60.45K

+31.7%

Return on Assets

-60.74%

N/A

Return on Invested Capital

-59.37%

N/A

Free Cash Flow

-SGD 2.35M

-129.7%

Operating Cash Flow

-SGD 2.05M

-163.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
LSTALisata Therapeutics, Inc.
$1.18-2.48%
NCNANuCana plc
$1.43-0.69%
SONNSonnet BioTherapeutics Holdings, Inc.
$1.26-59.35%
XCURExicure, Inc.
$1.30-7.14%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$146.15+0.10%
SMCISuper Micro Computer
$37.61+0.19%
INTCIntel
$100.95+0.03%
NOKNokia
$10.32+0.09%

Questions About GDTC

What is the current price of CytoMed Therapeutics?

CytoMed Therapeutics is trading at $0.81 per share.

What is the 52-week range for CytoMed Therapeutics?

Over the past 52 weeks, CytoMed Therapeutics has traded between $0.68 and $3.68.

How much debt does CytoMed Therapeutics have?

As of the most recent reporting period, CytoMed Therapeutics reported total debt of SGD 375.24K.

How much cash does CytoMed Therapeutics have on hand?

CytoMed Therapeutics reported SGD 1.63M in cash and cash equivalents in its most recent financial results.

What is CytoMed Therapeutics’s dividend yield?

CytoMed Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services